Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JASPER: Ruxolitinib and Enzalutamide in Castration-Resistant Prostate Cancer
NCT06616155Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in castration-resistant prostate cancer (CRPC), sponsored by University of Michigan Rogel Cancer Center. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06616155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616155.